



Protalix Biotherapeutics to Present at Four Upcoming Healthcare Conferences

May 13, 2010

CARMIEL, Israel, May 13, 2010 /PRNewswire via COMTEX/ --Protalix Biotherapeutics, Inc. (NYSE-AMEX: PLX), today announced it will present at four upcoming healthcare conferences.

Oppenheimer's 11th Annual Israeli
Conference □
May 16, 2010 at 11:50 AM IDT
David Intercontinental Hotel, Tel-Aviv

Citi 2010 Global Health Care Conference
May 26, 2010 at 3:00 PM ET
The Hilton New York Hotel, New York City
A webcast of this presentation will be
available at www.protalix.com on the
event calendar page

Jefferies 2010 Global Life Sciences
Conference □
June 8, 2010 at 3:30 PM ET
The Grand Hyatt Hotel, New York City
A webcast of this presentation will be
available at www.protalix.com on the
event calendar page

9th National Life Science and Technology
Week ISLI-Biomed Israel 2010
June 14-16, 2010
David Intercontinental Hotel, Tel-Aviv

About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. In August 2009, the FDA granted orphan drug status and fast track designation to taliglucerase alfa for the treatment of Gaucher disease and Protalix filed a rolling NDA submission with the FDA in December 2009. In November 2009, Protalix granted Pfizer Inc. exclusive, worldwide rights to develop and commercialize taliglucerase alfa for the treatment of Gaucher disease, except in Israel. Protalix retained the right to commercialize taliglucerase alfa in Israel.

Contact: □
Marcy Nanus
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com

SOURCE Protalix Biotherapeutics, Inc.